Research Finds Ritalin's Benefits in Treating Children with Autism

November 19, 2009 By Darci Slate,

(PhysOrg.com) -- UA researchers present evidence that the Ritalin is effective in treating preschoolers with Autism in a first-ever clinical trial to test the medication's efficacy with children with the disorder.

Dr. Jaswinder K. Ghuman, associate professor of psychiatry and pediatrics with the University of Arizona College of Medicine, and her colleagues, broke new ground with the first ever randomized-control trial of methylphenidate (Ritalin) treatment in preschool with , known as ASD.

The study's results were published in the Journal of Child and Adolescent Psychopharmacology, and were selected as the feature paper by the journal's editors.

Recently, increasingly higher rates of autism are being reported in the United States.

The most recent Center for Disease Control Autism Surveillance Project estimates that 1 in 150 children in the United States have an ASD.

Symptoms of Attention-Deficit/Hyperactivity Disorder, or , are very common in children with ASD. ADHD symptoms in children with ASD interfere with performing well in school and achieving age-appropriate developmental milestones.

Methylphenidate and other stimulant medications are commonly used to treat ADHD in children, including preschool-age children. Unfortunately, there is a serious lack of information regarding the safety and efficacy of these medications in preschool-age children.

Ghuman and her colleagues found that the preschoolers with ASD showed modest improvement and 50 percent responded positively to methylphenidate.

Methylphenidate response in the preschool participants was more subtle and variable compared to typically-developing ADHD children.

Nevertheless, parents were able to detect methylphenidate effects and were pleased with the change in their children's behavior, however modest it might have been; and more than 71 percent of the parents wanted their child to continue taking methylphenidate at the end of the study.

Preschoolers with ASD were sensitive to the side effects of methylphenidate, tolerated lower doses, required a slower rate of titration, and needed close monitoring for side effects.

The frequency and type of side effects were similar to the side effects seen with older children with ASD and preschoolers with intellectual disability.

"Our research shows that preschoolers with ASD and ADHD can benefit from a trial with methylphenidate," said Ghuman. "However, both children with ASD and children with ADHD are more sensitive to methylphenidate . Hence, preschoolers should be monitored closely and methylphenidate dose should be increased slowly and carefully."

Provided by University of Arizona (news : web)

Related Stories

Recommended for you

Anxious women may want to keep an eye on their bone health

May 18, 2018
(HealthDay)—As if older women didn't already worry enough about their bone health, new research suggests that anxiety may up their risk for fractures.

FDA approves first drug aimed at preventing migraines

May 18, 2018
(HealthDay)—The millions of Americans who suffer from migraine may have a new source of hope—the first drug aimed at preventing the headaches gained U.S. Food and Drug Administration approval on Thursday.

New strategy to cure chronic hepatitis B infection

May 18, 2018
Scientists from Karolinska Institutet and Hannover Medical School have published two studies that provide insights into how the immune system responds and helps to clear a hepatitis B infection after treatment interruption. ...

Blood type affects severity of diarrhea caused by E. coli

May 17, 2018
A new study shows that a kind of E. coli most associated with "travelers' diarrhea" and children in underdeveloped areas of the world causes more severe disease in people with blood type A.

Resistance to antifungal drugs could lead to disease and global food shortages

May 17, 2018
Growing levels of resistance to antifungal treatments could lead to increased disease outbreaks and affect food security around the world.

Pig immunology comes of age: Killer T cell responses to influenza

May 17, 2018
Researchers from The Pirbright Institute, University of Bristol, Cardiff University and University of Oxford have generated tools that allow scientists to understand a vital area of the pig immune system which was previously ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.